Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tremelimumba

Bristol-Myers Squibb (BMS) building

Opdivo cleared for kidney cancer and first-line melanoma

First drug to show survival benefit in kidney cancer since 2007

Roche Basel Switzerland

Roche posts positive Cotellic data ahead of anticipated EU approval

Comes after FDA and Swiss approvals and CHMPrecommendation

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy receives additional FDA approval

Gives the nod for Yervoy as adjuvant treatment option for melanoma

- PMLiVE

Amgen gets FDA nod for virus-based melanoma therapy

Advisory committee votes in favour of drug after three month delay

- PMLiVE

Amgen’s Imlygic recommended for European approval

First-in-class oncolytic immunotherapy wins CHMP positive opinion

Bristol-Myers Squibb (BMS) building

BMS bags US approval for Opdivo and Yervoy combo

Marks first approval for joint use of two immuno-oncology drugs

- PMLiVE

AZ opens new research centre with Cancer Research UK

MedImmune partners with CRUK in Cambridge-based R&D hub

- PMLiVE

NICE hands Merck & Co’s Keytruda speedy recommendation

Cancer drug backed for NHS use against advanced melanoma

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

- PMLiVE

Novartis bags EU approvals for three ex-GSK drugs

Revolade, Tafinlar and Mekinist all receive regulatory approval

- PMLiVE

Roche wins first approval for skin cancer drug Cotellic

Swissregulators give the Exelixis-discovered treatment the green light

- PMLiVE

AZ adds cancer vaccine to immuno-oncology portfolio

Firm's biologics unit adds to string of oncology deals in 2015

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links